Doseloop Beta

Acetazolamide

medication Under review

A carbonic anhydrase inhibitor medication used to treat glaucoma, altitude sickness, epilepsy, and fluid retention.

Research summary

AI-Generated Content: This summary was created by AI and may contain errors. Always verify with peer-reviewed sources.

Scientific evidence from randomized controlled trials in healthy humans primarily supports acetazolamide's role in preventing acute mountain sickness and mitigating high-altitude physiological impairments during ascent. Studies demonstrate improvements in ventilation, tissue oxygenation, visuomotor performance, and pulmonary hemodynamics at simulated or real high altitudes, with consistent prophylactic benefits at doses of 125-375 mg daily. Consensus indicates it optimizes brain oxygenation and reduces inflammation markers under hypoxic conditions, though effects on baseline healthy states without altitude exposure remain limited.

Reported Benefits

No side effects tracked yet

No side effects have been reported by studies or users for this habit yet.

Research (6 studies)

RCT

Effect of Acetazolamide on Pulmonary Hemodynamics and Right Ventricular Function in Healthy Subjects

Journal of the American Heart Association • 2025 • n=171

Not specified in available data

RCT

The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

ClinicalTrials.gov • 2024

Not specified in available data

RCT

Visuomotor performance at high altitude in COPD patients. Randomized placebo-controlled trial of acetazolamide.

High Altitude Medicine & Biology • 2023 • n=59

Not specified in available data

RCT

Sickness Evaluation at Altitude With Acetazolamide at Relative Doses

ClinicalTrials.gov • 2019

Not specified in available data

RCT

Acetazolamide during acute hypoxia improves tissue oxygenation in the human brain.

Journal of Applied Physiology • 2015

Not specified in available data

RCT

Drug Controls High-altitude Illness

American Journal of Respiratory and Critical Care Medicine • 2007 • n=9

Marc J. Poulin et al.

Community updates

No updates yet for this supplement.

Be the first to share your experience!

At a glance

Users tracking 0
Linked studies 6
Researched benefits 4
Side effects noted 0